MTLS

Materialise

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 50%
Negative

Positive
Zacks Investment Research
3 days ago
Best Stocks to Buy Before June 2026: 3 Breakout Stocks Ready to Surge
MTLS, LXFR and ARKO emerged as June breakout stock picks after strong gains and screening tied to price momentum and resistance levels.
Best Stocks to Buy Before June 2026: 3 Breakout Stocks Ready to Surge
Positive
Zacks Investment Research
21 days ago
Are Investors Undervaluing Materialise (MTLS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Materialise (MTLS) Right Now?
Positive
MarketBeat
24 days ago
Materialise Q1 Earnings Call Highlights
Materialise NASDAQ: MTLS reported first-quarter 2026 revenue of EUR 66.3 million, which Chief Financial Officer Koen Berges said was stable year-over-year despite “significant foreign exchange headwinds,” primarily tied to a weaker U.S. dollar. Gross profit rose to EUR 37.9 million and gross margin expanded to 57.2%, helping drive improved profitability and positive free cash flow during the period.
Materialise Q1 Earnings Call Highlights
Neutral
Seeking Alpha
25 days ago
Materialise NV (MTLS) Q1 2026 Earnings Call Transcript
Materialise NV (MTLS) Q1 2026 Earnings Call Transcript
Materialise NV (MTLS) Q1 2026 Earnings Call Transcript
Neutral
Business Wire
26 days ago
Materialise Reports First Quarter 2026 Results
LEUVEN, Belgium--(BUSINESS WIRE)--Materialise NV (Euronext & NASDAQ:MTLS), a global leader in 3D-printed medical devices and software, and a pioneer in additive manufacturing software and services, today announced its financial results for the first quarter ended March 31, 2026. Additionally, Materialise announced the transfer of its eyewear business to the eyewear management team. Highlights – First Quarter 2026 Total revenue was stable at 66,276 kEUR for the first quarter of 2026 compared.
Materialise Reports First Quarter 2026 Results
Positive
Seeking Alpha
1 month ago
Materialise: The Medical Segment Alone Makes This A Buy
Materialise receives a 'Buy' rating, driven by robust growth in its medical segment despite weakness in software and manufacturing. MTLS's medical segment boasts a 4-year CAGR of 16%, with management guiding for continued strong growth through FY2026. The company maintains a fortress balance sheet with €71m net cash and trades at a significant discount to sector peers on EV/Sales and EV/EBITDA.
Materialise: The Medical Segment Alone Makes This A Buy
Neutral
Business Wire
1 month ago
Materialise NV to Report First Quarter 2026 Earnings on Thursday, May 7, 2026
LEUVEN, Belgium--(BUSINESS WIRE)--Materialise NV (Euronext & NASDAQ: MTLS), a global leader in 3D-printed medical devices and software, and a pioneer in additive manufacturing software and services, today announced that it will release financial results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026 at 1:00 a.m. ET/7:00 a.m. CET. Senior management will hold a conference call to discuss the first quarter 2026 financial results on Thursday, May 7, 2026 at 8:30 a.m. ET/2:3.
Materialise NV to Report First Quarter 2026 Earnings on Thursday, May 7, 2026
Neutral
GlobeNewsWire
2 months ago
Materialise to Transfer RapidFit Business to Its Management Team
Leuven (BELGIUM), March 31, 2026 (GLOBE NEWSWIRE) -- Materialise NV (Euronext & Nasdaq: MTLS), a global leader in 3D-printed medical devices and software, and a pioneer in additive manufacturing software and services, announces the decision to transfer its RapidFit business to its management team. Following the transaction, RapidFit will continue as an independent company under the ownership and leadership of the same team under the RapidFit name.
Materialise to Transfer RapidFit Business to Its Management Team
Positive
Seeking Alpha
3 months ago
Materialise: Medical And Software-Led Rebound
Materialise is poised for a return to consistent growth and improving margins, led by Medical strength and stabilization of its Software business. The Manufacturing segment faces ongoing headwinds, but expansion into aerospace and defense could create a modest rebound over the next few years. The combination of a low valuation, consistent growth, and higher margins should lead the stock higher, which will be supported by a share buyback program.
Materialise: Medical And Software-Led Rebound
Neutral
Seeking Alpha
3 months ago
Materialise NV (MTLS) Q4 2025 Earnings Call Transcript
Materialise NV (MTLS) Q4 2025 Earnings Call Transcript
Materialise NV (MTLS) Q4 2025 Earnings Call Transcript